<DOC>
	<DOC>NCT03027609</DOC>
	<brief_summary>Prospective, double-blind, randomized assessment of the efficacy, safety and pharmacokinetic of Aerucin® as adjunct treatment (in addition to standard of care antibiotics) for pneumonia caused by P. aeruginosa.</brief_summary>
	<brief_title>Aerucin® in P. Aeruginosa Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<criteria>informed consent ≥18 years of age pneumonia due to P aeruginosa intubated APACHE II score between 10 and 35 Exclusion Criteria (main criteria): being moribund effective antibiotic therapy ≥48 hours immunocompromised underlying pulmonary disease that may preclude the assessment of a therapeutic response</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pseudomonas aeruginosa</keyword>
	<keyword>pneumonia</keyword>
</DOC>